Indivior sets USD 8.13 special dividend tied to Supernus merger closing
INDV•Special dividend tied to merger closing
- Indivior Pharmaceuticals is pursuing a merger with Supernus, targeted to close on or about Nov. 2, 2026.
- The deal triggers a contingent special cash dividend of $8.13 per Indivior share to holders of record on Oct. 30, 2026.
- Dividend payment is expected on or about Nov. 6, 2026 if the merger closes; it will not be paid if the deal fails.
- Supernus shareholders will not receive the dividend on any Indivior shares issued as merger consideration.
